Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00314366Phase 1Completed

Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

Role: collaborator

NCT00442533Phase 2Completed

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Role: collaborator

NCT02190500Phase 2Unknown

BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit

Role: collaborator

NCT03147768Phase 1Completed

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

Role: collaborator

NCT00661232Completed

Multicenter Myocardial Viability Trial

Role: lead

NCT00203203Phase 1Completed

Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)

Role: collaborator

All 6 trials loaded